This agreement facilitates the development of Nuclera’s second-generation eProtein Discovery system that will deliver breakthrough rapid access to highly complex, custom protein reagents.
Such rapid access to proteins will facilitate the acceleration of drug discovery by pharmaceutical companies and university research laboratories around the world.
Nuclera’s current benchtop system is the first and only product that miniaturises, simplifies and automates protein design and protein expression and purification screening, thereby giving bioscientists and engineers the ability to have reliable access to custom protein reagents in less than 48 hours.
The partnership with Sharp Life Science EU (SLS-EU) will help Nuclera to develop future generations of the eProtein Discovery system to provide ever more advanced features to drug discovery researchers.
Dr Michael C. Chen, Nuclera’s cofounder and CEO, said: “We are delighted to reach an agreement with SLS-EU, a world leader in the life sciences technology equipment industry, to exclusively licence its digital microfluidic IP portfolio."
"This not only helps us build our eProtein Discovery roadmap towards an even more advanced platform, but also facilitates the commercialisation of our digital microfluidic technologies, which means we empower our drug discovery customers to develop better, life-saving therapies faster."
